Lupin Limited has announced the strategic spin-off of two key oncology programs, LNP7457 (PRMT5) and LNP8701 (SOS1), through its U.S. subsidiary into Kaveri Therapeutics Inc. This move aims to advance these programs through global clinical trials. The deal involves an exclusive perpetual license in exchange for an 82.2% equity stake in Kaveri and seed funding. The programs are valued at USD 1.6 million.
Strategic Oncology Program Spin-off
Lupin Limited, a global pharmaceutical leader, announced on July 21, 2026, the strategic spin-off of two significant oncology programs: LNP7457 (PRMT5) and LNP8701 (SOS1). These programs have been transferred through its wholly-owned subsidiary, Lupin Inc., to Kaveri Therapeutics Inc. (Kaveri), a U.S.-based clinical-stage oncology company. This strategic move is designed to accelerate the advancement of these promising oncology assets through global clinical trials.
Deal Structure and Valuation
Under the terms of the agreement, Lupin Inc. will receive an 82.2% equity stake in Kaveri Therapeutics, which includes 332,000 Common Shares. In addition to the equity stake, Lupin Inc. will provide seed funding to Kaveri and grant them an exclusive perpetual license for the two oncology programs. The combined value of the license for these two programs is estimated at USD 1.6 million.
Kaveri Therapeutics’ Role and Future
Kaveri Therapeutics, established with an initial share capital on May 20, 2026, will operate as an independent entity. Its primary focus will be on advancing the LNP7457 and LNP8701 programs through global clinical trials and raising additional capital for further development. The company’s pipeline includes programs targeting PRMT5 and SOS1/RAS-pathway biology, with initial development focus on solid tumors such as lung, pancreatic, and ovarian cancers. Both programs have shown encouraging progress, with positive data reported at the American Society of Clinical Oncology (ASCO) meetings in 2025 and 2026.
Lupin’s Strategic Rationale
The spin-off aligns with Lupin’s strategy to expedite the development of targeted oncology therapies. Vinita Gupta, Chief Executive Officer of Lupin, expressed confidence that the strength of these assets, combined with Kaveri’s leadership team, will accelerate innovation for patients. Kaveri’s leadership includes CEO Kristi Jones and Chief Medical Officer Dr. Robert Pierce, bringing extensive experience in biopharmaceutical development.
Target Entity Details
Kaveri Therapeutics, Inc. was incorporated on May 20, 2026, in Delaware, U.S.A. The company is a clinical-stage oncology firm focused on the early-stage development of therapies for solid tumors. As of the announcement, Kaveri reported a turnover of NIL and a Net Worth of NIL, with no related party transactions involved in this acquisition. The transaction was completed simultaneously with the execution of the licensing arrangement on July 20, 2026.
Source: BSE
